Ryan Pardo, an officer of LifeStance Health Group, Inc., filed a Form 144 notice on November 10, 2026, disclosing a proposed sale of 587,920 shares of LifeStance common stock with an aggregate market value of $8,466,048, to be executed through Merrill Lynch Pierce Fenner and Smith on NASDAQ.

Key Highlights

  • Proposed sale: 587,920 shares of LifeStance Health Group common stock with an aggregate market value of $8,466,048, according to the filing.
  • Selling officer: Ryan Pardo is identified as an officer of LifeStance Health Group, Inc. (NASDAQ:LFST), with the sale to be made from the Pardo Family Rev Trust.
  • Shares outstanding: The filing states 380,190,724 shares of common stock outstanding at the time of the notice.
  • 10b5-1 plan: The filing indicates a trading plan or instruction was adopted on August 11, 2026, with a notice date of November 10, 2026.
  • Acquisition history: The shares proposed for sale were acquired between June 9, 2022 and April 1, 2025, through compensation transactions from the issuer, paid in cash.
  • No sales in past 3 months: The filing reports nothing to report under securities sold during the past three months.

LifeStance Officer Ryan Pardo Files Rule 144 Notice for Proposed Stock Sale

According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 10, 2026, Ryan Pardo, identified as an officer of LifeStance Health Group, Inc., has provided notice of a proposed sale of 587,920 shares of common stock. The filing states that the approximate date of sale is November 10, 2026, and that the transaction is to be executed through Merrill Lynch Pierce Fenner and Smith, located in Burlington, Massachusetts, on the NASDAQ exchange.

The filing discloses that the shares to be sold were acquired through ten separate compensation transactions from the issuer between June 9, 2022 and April 1, 2025. The individual acquisition amounts range from 13,998 shares to 104,567 shares, with each transaction settled in cash. The aggregate market value of the proposed sale is listed as $8,466,048, against a total of 380,190,724 shares of common stock outstanding as reported in the filing. The filing notes in the remarks section that the sale is to be made from the Pardo Family Rev Trust.

The filing further indicates that Pardo is relying on Rule 10b5-1, with a plan adoption or instruction date of August 11, 2026. Under the Form 144's attestation language, the signer represents that he does not know any material adverse information regarding the current and prospective operations of the issuer that has not been publicly disclosed, as of the plan adoption date. No securities of the issuer were reported as sold by Pardo during the three months preceding this notice.

What Was Disclosed

LifeStance Health Group officer Ryan Pardo filed a Form 144 notice on November 10, 2026, covering a proposed sale of 587,920 common shares valued at $8,466,048, to be conducted through Merrill Lynch under a Rule 10b5-1 plan adopted August 11, 2026, from the Pardo Family Rev Trust.